Which bacteria are most often treated with tigecycline?
Tigecycline is commonly used for serious infections when clinicians need coverage that includes several Gram-positive and Gram-negative bacteria, particularly in complicated cases. In practice, the bacteria most often associated with tigecycline treatment are:
- Multidrug-resistant (MDR) and healthcare-associated Gram-negative rods, including Enterobacterales (such as Escherichia coli and Klebsiella pneumoniae) and other non-fermenters like Acinetobacter baumannii.
- Resistant Gram-positive organisms, including methicillin-resistant Staphylococcus aureus (MRSA) and resistant Enterococcus species.
- Certain anaerobes in complicated polymicrobial infections, where tigecycline’s spectrum can help cover mixed flora.
What types of infections lead doctors to choose tigecycline?
Tigecycline is typically considered when infections are complicated or when resistance limits other options. The bacteria above are most often targeted in conditions such as:
- Complicated intra-abdominal infections, where mixed Gram-negative and anaerobic bacteria are common.
- Complicated skin and soft-tissue infections, including cases involving resistant Gram-positive organisms and healthcare-associated Gram-negative pathogens.
- Nosocomial infections involving MDR Gram-negative bacteria (including Acinetobacter species).
Does tigecycline treat Pseudomonas or Proteus?
Tigecycline is not a go-to choice for many classic difficult-to-treat pathogens such as Pseudomonas aeruginosa. In typical clinical use, clinicians rely on other agents for Pseudomonas and many other organisms that fall outside tigecycline’s strongest covered groups. The bacteria most associated with tigecycline use are more often Enterobacterales, Acinetobacter baumannii, MRSA, and susceptible anaerobic partners in polymicrobial infections.
What to know about resistant strains?
Tigecycline is used in part because it can retain activity against some multidrug-resistant strains that resist many standard antibiotics. The key “resistance context” behind tigecycline use is MDR healthcare pathogens, especially among Gram-negative bacteria and MRSA.
Are there specific organisms clinicians test before using it?
In real-world prescribing, clinicians generally base tigecycline choice on:
- The suspected source of infection (for example, intra-abdominal vs. skin/soft tissue).
- Local antibiogram patterns.
- Culture and susceptibility results, since tigecycline’s appropriateness depends on whether the isolated organism is susceptible.
If you tell me the infection site (for example, intra-abdominal, skin/soft tissue, pneumonia) and whether it’s community-acquired or hospital-acquired, I can narrow the likely bacteria most commonly covered by tigecycline for that scenario.